Higher Cumulative Isotretinoin Dose May Reduce Acne Relapse

A Common Challenge After Isotretinoin

Isotretinoin remains the gold standard for treating severe acne and is the only medical therapy capable of inducing long-term remission, yet relapse remains a frustrating reality for both patients and clinicians. Previous Dermatology Times coverage has highlighted evolving approaches to isotretinoin therapy and acne management as clinicians continue to balance treatment efficacy, tolerability, and long-term outcomes.

Despite isotretinoin's effectiveness, questions remain about which patients are most likely to relapse and whether treatment strategies can reduce that risk.

A new cohort study published in JAMA Dermatology examined nearly 20,000 patients who completed an initial course of isotretinoin, identifying factors associated with acne relapse and retreatment while offering new insights into how dosing strategies may influence long-term outcomes.¹

Cumulative Dose May Matter More Than Daily Dose

Researchers analyzed commercial claims data from 19,907 patients aged 12 years or older who completed at least 4 months of isotretinoin therapy. Overall, 22.5% experienced acne relapse requiring additional systemic treatment, while 8.2% required a second course of isotretinoin. These findings underscore that relapse remains relatively common despite successful completion of isotretinoin therapy.

Higher cumulative isotretinoin dosage was associated with lower rates of both acne relapse and isotretinoin retrial. In contrast, among patients who achieved conventional cumulative dosing (120-220 mg/kg) or higher, increasing the maximum daily dose was not associated with lower relapse or retreatment rates.

Together, these findings suggest that achieving an adequate cumulative dose may be more important than increasing daily dose once conventional cumulative dosing has been reached, allowing clinicians greater flexibility to individualize treatment based on tolerability and patient preferences.¹

Who Was Most Likely to Relapse?

Female patients experienced significantly higher rates of acne relapse than male patients, although they were less likely to undergo a second course of isotretinoin. The investigators noted that greater use of spironolactone among female patients and logistical barriers associated with iPLEDGE requirements may partially explain this finding.

Among patients who relapsed, oral antibiotics were the most commonly prescribed systemic therapy after isotretinoin, followed by repeat isotretinoin courses and spironolactone. The median time to relapse was 7.5 months after completing treatment, although nearly one-third of relapses occurred more than a year later.¹

Potential Implications for Acne Management

The findings build on existing evidence supporting cumulative isotretinoin exposure as an important determinant of long-term remission. Notably, investigators found no additional benefit to cumulative doses exceeding 220 mg/kg, suggesting that escalating treatment beyond this threshold may offer limited value for preventing relapse.¹

As dermatologists continue to personalize acne treatment, these findings may help inform discussions surrounding cumulative dose targets, adverse effect management, and patient counseling regarding relapse risk. They also arrive as clinicians continue balancing treatment efficacy with tolerability, particularly for patients who struggle with dose-related adverse effects during isotretinoin therapy.

Study Limitations

The authors noted several limitations, including reliance on insurance claims data and the absence of individual patient weight, requiring weight-based dosing estimates using national reference data. Acne relapse was defined by subsequent systemic acne prescriptions, which may not always reflect true relapse, and clinical information such as acne severity, treatment adherence, and over-the-counter medication use was unavailable. Additionally, because the database primarily included commercially insured patients, the findings may not be generalizable to all populations.¹

What This Means for Clinicians

Although the findings are unlikely to immediately change clinical practice, they reinforce the importance of cumulative isotretinoin exposure when counseling patients and planning treatment courses. Rather than focusing solely on increasing daily dose, dermatologists may be able to individualize treatment based on tolerability while still ensuring patients reach cumulative dose targets associated with more durable remission.

References:

Lai J, Barbieri JS. Acne Relapse and Isotretinoin Retrial in Patients With Acne.JAMA Dermatology. 2025;161(4):367-374. doi:10.1001/jamadermatol.2024.5416.